Biosimilar development challenges

Biosimilars are surmounting pharmaceutical business division from most recent three decades and deals appear to extend coherently. Advances in the biotechnology prompt to change and exposure of new natural items (biosimilars) to treat diverse life-debilitating illnesses. Biosimilars are organic medications that are conveyed after expiry of the patent of affirmed pioneer and include Hatch-Waxman act is the amendment to Federal, Food, Drug and Cosmetics act which established the modern system of approval of generics through Abbreviated New Drug Applications (ANDAs).

  • Biosimilar development challenges
  • Overview of the current and emerging local trends
  • Key changes in the pipeline of biopharma products
  • Highlighting opportunities and challenges in Biomanufacturing

Biosimilar development challenges Conference Speakers

Recommended Sessions

Related Journals

Are you interested in